hotspot -WSS

hotspot

author：explore 2025-09-29 18:17:32 - browse：6

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： CDC backtracks, saying fully vaccinated people can go maskless indoors

focus

WSS

What don’t we know about an Alzheimer’s drug side effect?

Pediatric cancer treatments threatened by a new FDA policy

BIO selects John Crowley as new CEO

White House launches permanent pandemic office

In new study, freeze

Despite FDA concern, risk that CAR

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

Providers still hesitate to prescribe buprenorphine, study finds

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Cancer drug shortages should be causing more outrage

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Alkermes shareholders re

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Our daughter's deadly disease: trisomy 18. We wanted to protect her

focus

CDC director unscathed in first congressional testimony

Organ aging and disease risk measured by new blood test

Pediatric cancer treatments threatened by a new FDA policy

Death toll from an explosion and collapse of a Paris building in June climbs to 3

CDC director unscathed in first congressional testimony

BIO selects John Crowley as new CEO

focus

hotspot

Wikipedia

entertainment